Gyre Therapeutics, Inc.
GYRE
$8.46
-$0.3479-3.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 9.35% | 1.04% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.35% | 1.04% | |||
| Cost of Revenue | 22.86% | 24.42% | |||
| Gross Profit | 8.83% | 0.31% | |||
| SG&A Expenses | 27.38% | -1.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 28.01% | -3.22% | |||
| Operating Income | -84.34% | 29.77% | |||
| Income Before Tax | -80.36% | -34.88% | |||
| Income Tax Expenses | -81.10% | -28.26% | |||
| Earnings from Continuing Operations | -80.08% | -37.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 61.43% | -71.49% | |||
| Net Income | -108.81% | -68.14% | |||
| EBIT | -84.34% | 29.77% | |||
| EBITDA | -75.81% | 33.91% | |||
| EPS Basic | -109.16% | -68.28% | |||
| Normalized Basic EPS | -134.12% | -74.09% | |||
| EPS Diluted | -125.95% | 122.03% | |||
| Normalized Diluted EPS | -140.85% | -73.61% | |||
| Average Basic Shares Outstanding | 0.36% | 0.17% | |||
| Average Diluted Shares Outstanding | -16.26% | -1.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||